Lemborexant has 16 known drug interactions based on U.S. FDA drug labeling data. Of these, 11 are contraindicated combinations that should be avoided entirely. 1 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Bosentan, Carbamazepine, Clarithromycin. Patients taking Lemborexant should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 16
- Contraindicated
- 11
- Major
- 1
- Moderate
- 4
Contraindicated (11)
- Lemborexant + Bosentan— Moderate CYP3A inducer that decreases lemborexant exposure, which may reduce DAYVIGO efficacy. Concomitant use should be…
- Lemborexant + Carbamazepine— Strong CYP3A inducer that decreases lemborexant exposure, which may reduce DAYVIGO efficacy. Concomitant use should be a…
- Lemborexant + Clarithromycin— Strong CYP3A inhibitor that increases lemborexant AUC and Cmax, increasing risk of adverse reactions. Concomitant use sh…
- Lemborexant + Efavirenz— Moderate CYP3A inducer that decreases lemborexant exposure, which may reduce DAYVIGO efficacy. Concomitant use should be…
- Lemborexant + Etravirine— Moderate CYP3A inducer that decreases lemborexant exposure, which may reduce DAYVIGO efficacy. Concomitant use should be…
- Lemborexant + Fluconazole— Moderate CYP3A inhibitor that increases lemborexant AUC and Cmax, increasing risk of adverse reactions. Concomitant use …
- Lemborexant + Itraconazole— Strong CYP3A inhibitor that increases lemborexant AUC and Cmax, increasing risk of adverse reactions. Concomitant use sh…
- Lemborexant + Modafinil— Moderate CYP3A inducer that decreases lemborexant exposure, which may reduce DAYVIGO efficacy. Concomitant use should be…
- Lemborexant + Rifampin— Strong CYP3A inducer that decreases lemborexant exposure, which may reduce DAYVIGO efficacy. Concomitant use should be a…
- Lemborexant + St. John'S Wort— Strong CYP3A inducer that decreases lemborexant exposure, which may reduce DAYVIGO efficacy. Concomitant use should be a…
- Lemborexant + Verapamil— Moderate CYP3A inhibitor that increases lemborexant AUC and Cmax, increasing risk of adverse reactions. Concomitant use …
Major (1)
- Lemborexant + Alcohol— Increases lemborexant Cmax and AUC with greater negative impact on postural stability and memory when assessed near peak…
Moderate (4)
- Lemborexant + Bupropion— CYP2B6 substrate whose AUC is decreased by lemborexant, potentially reducing efficacy. Monitor for adequate clinical res…
- Lemborexant + Chlorzoxazone— Weak CYP3A inhibitor that increases lemborexant AUC and Cmax. Maximum recommended dose of lemborexant is 5 mg when used …
- Lemborexant + Methadone— CYP2B6 substrate whose AUC is decreased by lemborexant, potentially reducing efficacy. Monitor for adequate clinical res…
- Lemborexant + Ranitidine— Weak CYP3A inhibitor that increases lemborexant AUC and Cmax. Maximum recommended dose of lemborexant is 5 mg when used …